Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats
Research article published in Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (2007)
Abstract
OBJECTIVE: To promote the nasal absorption of recombinant hirudin-2, the preparation and physicochemical properties of recombinant hirudin-2 liposomes, as well as its pharmacokinetic characteristics and bioavailability in rats after nasal administration were investigated. METHOD: Recombinant hirudin-2 liposomes were prepared by reversal phase evaporation; the test of physicochemical properties including encapsulation efficiency, particle size and stability of liposome suspensions were determined by HPLC; Recombinant hirudin-2 concentration in plasma was determined by chromogenic substrate method and the relative bioavailability and pharmacokinetic parameters were also calculated using software program 3p87. RESULT: The encapsulation efficiency of recombinant hirudin-2 liposome reached greater than 76.95%, with an average particle size of about 168.3 nm, size distribution ranging from 24 to 286 nm, relative peak width of +/- 0.47, and a good stability. CONCLUSION: Compared with recombinant hirudin-2 solution, liposome preparation enhanced the nasal absorption of recombinant hirudin-2.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Recombinant hirudin-2 liposomes prepared by reverse-phase evaporation showed over 76.95% encapsulation efficiency, a mean particle size near 168.3 nm and good stability, and enhanced nasal absorption of recombinant hirudin-2 compared with solution in rats.
Why This Matters for Hirudotherapy
This study examined the preparation, physicochemical properties, and pharmacokinetics of recombinant hirudin-2 liposomes after nasal administration in rats. Prepared by reversal phase evaporation, the liposomes achieved encapsulation efficiencies above 76.95%, an average particle size of approximately 168.3 nm with good stability, and enhanced nasal absorption compared with recombinant hirudin-2 solution. The study explores an alternative delivery route for hirudin, a peptide widely recognized as a leech-derived anticoagulant central to hirudotherapy, although the abstract itself does not mention leech origin. This is a preclinical animal pharmacokinetic study with no clinical data; no leeches or hirudotherapy are directly involved.
Citation
Reference (Vancouver style)
Zhang YJ, Wang XL, Wu JM, Cheng MX. Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats. Zhongguo Zhong Yao Za Zhi. 2007;32(9):801-804. PMID: 17639978
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026